KCNQ Channels and Vasoconstrictor Signal Transduction
KCNQ 通道和血管收缩信号转导
基本信息
- 批准号:8403740
- 负责人:
- 金额:$ 36.23万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-01-15 至 2014-12-31
- 项目状态:已结题
- 来源:
- 关键词:A kinase anchoring proteinAcetylcholineAction PotentialsAddressAdrenergic AgonistsAffectAgonistAlzheimer&aposs DiseaseAngiotensin IIArgipressinArrhythmiaArteriesBindingBiochemicalBlood PressureBlood VesselsBlood flowBrainCaliberCardiacCardiac MyocytesCardiovascular DiseasesCarotid ArteriesCell LineCharacteristicsCo-ImmunoprecipitationsComplexConsciousDown-RegulationElectrocardiogramElectrophysiology (science)EnvironmentEpilepsyFamilyFamily memberGenerationsGenesHormonesImmunohistochemistryIn VitroIndividualKnock-in MouseLabyrinthLong QT SyndromeLungMaleimidesMass Spectrum AnalysisMeasuresMediator of activation proteinMembraneMembrane PotentialsMesenteric ArteriesMesenteryMethodsMicrospheresMinkModelingMolecularMolecular TargetMonitorMusMuscarinic Acetylcholine ReceptorMuscle CellsMutationMyocardiumMyographyNamesNeuronsNeurotransmittersPerfusionPharmaceutical PreparationsPhenylephrinePhosphorylationPhosphorylation SitePhosphotransferasesPhysiologicalPlayPotassium ChannelProcessProtein IsoformsProtein Kinase CProteinsPublishingRNA InterferenceRattusReagentRegulationRestRoleSerotoninSerotonin AgonistsSignal PathwaySignal TransductionSignal Transduction PathwaySkeletal MuscleSmooth MuscleSmooth Muscle MyocytesStructureSympathetic GangliaSystemTechniquesTestingThoracic aortaTimeTissuesTransgenic MiceVasoconstrictor AgentsVisceralVoltage-Gated Potassium Channelbasilar arteryblood pressure regulationcardiovascular disorder therapychannel blockerscongenital deafnessconstrictionfemoral arteryflupirtinehuman diseasein vivoinhibitor/antagonistinstrumentintravital microscopyknock-downlinopirdineloss of functionmembermouse modelneuronal excitabilityneurotransmitter releasenovelpatch clamppostsynapticpressureprotein expressionpublic health relevanceresponsevascular bedvasoconstrictionvoltage
项目摘要
DESCRIPTION (provided by applicant): KCNQ K+ channels have been implicated in human diseases ranging from cardiac arrhythmias to congenital deafness and epilepsy. In neurons, these channels underlie a voltage-sensitive K+ (Kv) current, which is negatively regulated by acetylcholine to regulate postsynaptic neuronal excitability. Although KCNQ channels had not previously been considered to play a role in vasoconstrictor signal transduction, we have recently shown that suggest that regulation of arterial myocyte excitability by physiological vasoconstrictor concentrations of arginine vasopressin (AVP, 10-100 pM) involves protein-kinase C-dependent suppression of KCNQ5 channel activity. We have also recently published evidence that this negative regulation of KCNQ channels underlies the vasoconstrictor actions of low [AVP] (30 pM) in rat mesenteric arteries. No previous studies have examined how KCNQ channels may be regulated by vasoactive hormones, the signal transduction mechanisms involved, whether their functions or regulation differ among vascular beds that express different channel subtypes, or whether these channels or signaling pathways may be useful targets for cardiovascular disease therapies. We therefore propose to: 1. Identify the subtypes of KCNQ family (Kv7.1- 7.5) channels expressed in arterial myocytes from rat mesenteric or basilar arteries and determine their functional roles in regulating artery diameter. Real time PCR and immunohistochemistry will be used to detect KCNQ channel expression. Channel function will be assessed by pressure myography in isolated arteries and patch clamp electrophysiology in isolated myocytes. Selective KCNQ channel blockers and activators and molecular knock-down approaches will be used to evaluate function of specific channel subtypes. 2. Identify the signal transduction mechanisms by which AVP (and potentially other vasoconstrictor hormones) regulate KCNQ channels. We will measure time- and concentration-dependent effects of AVP and other vasoconstrictor agonists (5-HT, AngII, and phenylephrine) on KCNQ currents in freshly isolated arterial myocytes. The roles of specific protein kinase C isoforms and A kinase-anchoring protein 150 (AKAP150) in KCNQ current regulation will be investigated using pharmacological activators/inhibitors or molecular reagents to disrupt their expression/function. The role of phosphorylation of specific residues on KCNQ channels (to be identified by mass spectrometry) will be evaluated by molecular targeting of the kinase or phosphorylation sites in cultured smooth muscle cells and by knocking in dysregulated KCNQ channels in transgenic mice. Molecules associated with KCNQ channels in signaling complexes will be identified using co-immunoprecipitation with native or FLAG-tagged KCNQ channel proteins. 3. Finally, the hypothesis that arterial KCNQ channels play an important role in vasoconstrictor actions and blood pressure regulation will be tested by measuring in vivo effects of selective KCNQ channel activators and blockers on mesenteric artery blood flow and systemic blood pressure measured acutely in anesthetized rats or in chronically instrumented conscious rats.
描述(由申请人提供):KCNQ K+通道与心律失常、先天性耳聋和癫痫等人类疾病有关。在神经元中,这些通道是电压敏感的 K+ (Kv) 电流的基础,该电流受到乙酰胆碱的负调节,以调节突触后神经元的兴奋性。虽然 KCNQ 通道以前未被认为在血管收缩信号转导中发挥作用,但我们最近表明,精氨酸加压素(AVP,10-100 pM)的生理血管收缩浓度对动脉肌细胞兴奋性的调节涉及蛋白激酶 C- KCNQ5 通道活性的依赖性抑制。我们最近还发表了证据,表明 KCNQ 通道的这种负调节是大鼠肠系膜动脉中低 [AVP] (30 pM) 血管收缩作用的基础。之前没有研究探讨 KCNQ 通道如何受血管活性激素调节、涉及的信号转导机制、表达不同通道亚型的血管床之间它们的功能或调节是否不同,或者这些通道或信号通路是否可能是心血管疾病的有用靶点疗法。因此,我们建议: 1. 鉴定大鼠肠系膜或基底动脉的动脉肌细胞中表达的 KCNQ 家族 (Kv7.1-7.5) 通道的亚型,并确定其在调节动脉直径中的功能作用。实时PCR和免疫组织化学将用于检测KCNQ通道表达。将通过离体动脉的压力肌电描记法和离体肌细胞的膜片钳电生理学来评估通道功能。选择性 KCNQ 通道阻断剂和激活剂以及分子敲低方法将用于评估特定通道亚型的功能。 2. 确定 AVP(以及可能的其他血管收缩激素)调节 KCNQ 通道的信号转导机制。我们将测量 AVP 和其他血管收缩激动剂(5-HT、AngII 和去氧肾上腺素)对新鲜分离的动脉肌细胞中 KCNQ 电流的时间和浓度依赖性影响。将使用药理学激活剂/抑制剂或分子试剂破坏其表达/功能来研究特定蛋白激酶 C 亚型和 A 激酶锚定蛋白 150 (AKAP150) 在 KCNQ 电流调节中的作用。 KCNQ 通道上特定残基磷酸化的作用(通过质谱法鉴定)将通过培养平滑肌细胞中激酶或磷酸化位点的分子靶向以及通过敲入转基因小鼠中失调的 KCNQ 通道来评估。信号复合物中与 KCNQ 通道相关的分子将通过与天然或 FLAG 标记的 KCNQ 通道蛋白的免疫共沉淀来鉴定。 3. 最后,动脉 KCNQ 通道在血管收缩作用和血压调节中发挥重要作用的假设将通过测量选择性 KCNQ 通道激活剂和阻断剂对麻醉大鼠急性测量的肠系膜动脉血流和全身血压的体内影响来检验或在长期接受仪器检测的有意识的老鼠中。
项目成果
期刊论文数量(10)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Diclofenac distinguishes among homomeric and heteromeric potassium channels composed of KCNQ4 and KCNQ5 subunits.
双氯芬酸区分由 KCNQ4 和 KCNQ5 亚基组成的同聚和异聚钾通道。
- DOI:
- 发表时间:2011-01
- 期刊:
- 影响因子:3.6
- 作者:Brueggemann, Lioubov I;Mackie, Alexander R;Martin, Jody L;Cribbs, Leanne L;Byron, Kenneth L
- 通讯作者:Byron, Kenneth L
Activation of vascular KCNQ (Kv7) potassium channels reverses spasmogen-induced constrictor responses in rat basilar artery.
血管 KCNQ (Kv7) 钾通道的激活可逆转大鼠基底动脉中痉挛原诱导的收缩反应。
- DOI:
- 发表时间:2011-09
- 期刊:
- 影响因子:7.3
- 作者:Mani, Bharath K;Brueggemann, Lioubov I;Cribbs, Leanne L;Byron, Kenneth L
- 通讯作者:Byron, Kenneth L
KCNQ (Kv7) potassium channel activators as bronchodilators: combination with a β2-adrenergic agonist enhances relaxation of rat airways.
KCNQ (Kv7) 钾通道激活剂作为支气管扩张剂:与 β2 肾上腺素能激动剂组合可增强大鼠气道的松弛。
- DOI:10.1152/ajplung.00253.2013
- 发表时间:2014-03-15
- 期刊:
- 影响因子:0
- 作者:L. Brueggemann;Jennifer M. Haick;Samantha Neuburg;Shawn Tate;D. R;hawa;hawa;L. Cribbs;K. Byron
- 通讯作者:K. Byron
Vascular KCNQ (Kv7) potassium channels as common signaling intermediates and therapeutic targets in cerebral vasospasm.
血管 KCNQ (Kv7) 钾通道作为脑血管痉挛的常见信号中间体和治疗靶点。
- DOI:
- 发表时间:2013-01
- 期刊:
- 影响因子:3
- 作者:Mani, Bharath K;O'Dowd, James;Kumar, Lalit;Brueggemann, Lioubov I;Ross, Masey;Byron, Kenneth L
- 通讯作者:Byron, Kenneth L
Kv7.5 Potassium Channel Subunits Are the Primary Targets for PKA-Dependent Enhancement of Vascular Smooth Muscle Kv7 Currents.
Kv7.5 钾通道亚基是 PKA 依赖性增强血管平滑肌 Kv7 电流的主要目标。
- DOI:
- 发表时间:2016-03
- 期刊:
- 影响因子:3.6
- 作者:Mani, Bharath K;Robakowski, Christina;Brueggemann, Lyubov I;Cribbs, Leanne L;Tripathi, Abhishek;Majetschak, Matthias;Byron, Kenneth L
- 通讯作者:Byron, Kenneth L
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KENNETH L BYRON其他文献
KENNETH L BYRON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KENNETH L BYRON', 18)}}的其他基金
KCNQ Channels in Airway Smooth Muscle Physiology and Disease
KCNQ 气道平滑肌生理学和疾病中的通道
- 批准号:
9210531 - 财政年份:2016
- 资助金额:
$ 36.23万 - 项目类别:
KCNQ Channels and Vasoconstrictor Signal Transduction
KCNQ 通道和血管收缩信号转导
- 批准号:
8024529 - 财政年份:2009
- 资助金额:
$ 36.23万 - 项目类别:
KCNQ Channels and Vasoconstrictor Signal Transduction
KCNQ 通道和血管收缩信号转导
- 批准号:
7582000 - 财政年份:2009
- 资助金额:
$ 36.23万 - 项目类别:
KCNQ Channels and Vasoconstrictor Signal Transduction
KCNQ 通道和血管收缩信号转导
- 批准号:
8206590 - 财政年份:2009
- 资助金额:
$ 36.23万 - 项目类别:
KCNQ Channels and Vasoconstrictor Signal Transduction
KCNQ 通道和血管收缩信号转导
- 批准号:
7758181 - 财政年份:2009
- 资助金额:
$ 36.23万 - 项目类别:
KCNQ Channels and Vasoconstrictor Signal Transduction
KCNQ 通道和血管收缩信号转导
- 批准号:
8024529 - 财政年份:2009
- 资助金额:
$ 36.23万 - 项目类别:
Calcium entry and vascular smooth muscle excitation
钙进入和血管平滑肌兴奋
- 批准号:
6609587 - 财政年份:2003
- 资助金额:
$ 36.23万 - 项目类别:
Calcium entry and vascular smooth muscle excitation
钙进入和血管平滑肌兴奋
- 批准号:
6891569 - 财政年份:2003
- 资助金额:
$ 36.23万 - 项目类别:
Calcium entry and vascular smooth muscle excitation
钙进入和血管平滑肌兴奋
- 批准号:
7058719 - 财政年份:2003
- 资助金额:
$ 36.23万 - 项目类别:
Calcium entry and vascular smooth muscle excitation
钙进入和血管平滑肌兴奋
- 批准号:
6749575 - 财政年份:2003
- 资助金额:
$ 36.23万 - 项目类别:
相似国自然基金
特异阻断α7乙酰胆碱受体的新型芋螺肽先导药物的发现
- 批准号:42376112
- 批准年份:2023
- 资助金额:51 万元
- 项目类别:面上项目
烟碱型乙酰胆碱受体变异介导普通大蓟马对多杀菌素抗性机制研究
- 批准号:32360663
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
伪旋毛虫乙酰胆碱酯酶破坏肠道ILC2s的ChAT-ACh通路实现免疫逃逸的机制研究
- 批准号:32302960
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
胆碱能神经元单囊泡胞吐释放乙酰胆碱的多维度电化学分析及应用研究
- 批准号:22374005
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
慢性应激诱导肺上皮分泌乙酰胆碱重塑乳腺癌肺转移前微环境的机制研究
- 批准号:82303386
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
KCNQ Channels and Vasoconstrictor Signal Transduction
KCNQ 通道和血管收缩信号转导
- 批准号:
8024529 - 财政年份:2009
- 资助金额:
$ 36.23万 - 项目类别:
KCNQ Channels and Vasoconstrictor Signal Transduction
KCNQ 通道和血管收缩信号转导
- 批准号:
7582000 - 财政年份:2009
- 资助金额:
$ 36.23万 - 项目类别:
KCNQ Channels and Vasoconstrictor Signal Transduction
KCNQ 通道和血管收缩信号转导
- 批准号:
7758181 - 财政年份:2009
- 资助金额:
$ 36.23万 - 项目类别:
KCNQ Channels and Vasoconstrictor Signal Transduction
KCNQ 通道和血管收缩信号转导
- 批准号:
8206590 - 财政年份:2009
- 资助金额:
$ 36.23万 - 项目类别:
KCNQ Channels and Vasoconstrictor Signal Transduction
KCNQ 通道和血管收缩信号转导
- 批准号:
8024529 - 财政年份:2009
- 资助金额:
$ 36.23万 - 项目类别: